The clinical research of Somatostatin Analogs with TACE in treatment of Hepatocellular Carcinoma

Objective To investigate the clinical value of Somatostatin Analogs(octreotide) with transcatheter hepatic arterial chemoembolization (TACE) in treatment of hepatocellular carcinoma(HCC).Methods 80 HCC patients without chance of operation were randomly divided into experimental group and control group,40 cases of each group.The tumor blood artery were cleared by hepatic artery angiography in experimental group,which were given lipiodol( 10 ～ 20 ml ) + pharmorubicin ( 10 ～ 30 mg ) + Hydroxycamptothecin ( 10 ～ 20 mg ),then local blood flow slowed down with gelatin sponge particles.After TACE patients received octreotide(0.3 mg/time/day) by continuous intravenous 5 days.Palients in control group were given the conventional protect liver treatment.All of the patients were treated three times,treatment interval for a month.Alpha-fetoprotein(AFP) changed after treatment; Tumor size,new liver cancer organizations and extrahepatic distant metastases were watched by abdominal CT; the recurrence rate,extrahepatic transfer rate and survival rate were calculated.Results Compared with control group,AFP of experimental group reduced more significantly (P＜ 0.05),short-term curative effect was better(P＜ 0.05).The recurrence rate,extrahepatic transfer rate and survival rate respectively was 22.9％,11.4％ and 91.4％ in experimental group; 46.9％、15.6％ and 71.9％ in control group.The extrahepatic transfer rate of the two groups has no significant difference (P＞ 0.05).The recurrence rate and survival rate of the two groups had significant difference(P＜ 0.05).Conelusion Compared with control group,experimental group has better short-term curative effect,lower recurrence rate and higher survival rate after one year,which have clinical significance for popularization. Key words: Somatostatin Analogs; Octreotide; Transcatheter hepatic arterial chemoembolization; Hepato-cellular carcinoma